Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Remedy Plan

Request full access

Developing Cancer Containment Therapy, a non-toxic approach to disrupting cancer spread

Gaithersburg, United StatesFounded 2011Biotech & Life Sciences

About Remedy Plan

Remedy Plan Therapeutics is a privately-held, clinical-stage pharmaceutical company focused on developing a novel class of small molecule therapeutics. Founded in 2011 by Gregory Crimmins and Ron Parchem, the Gaithersburg, Maryland-based firm is pioneering a solution to a long-standing challenge in drug development. Dr. Crimmins, who serves as CEO, holds a PhD in molecular biology from the University of California, Berkeley, and has two decades of biomedical research experience. His background in immunotherapy and phenotypic screening guided the company from its inception and the creation of its proprietary drug screening platform.

The company's core technology revolves around the inhibition of nicotinamide phosphoribosyltransferase (NAMPT), a critical enzyme that regulates how cells use energy. Dysregulation of NAMPT has been linked to over 20 diseases, including cancer, autoimmune disorders, and metabolic conditions, making it a high-value therapeutic target. For over 25 years, previous attempts by pharmaceutical companies to target NAMPT were hindered by severe on-target toxicities in healthy tissues. Remedy Plan's distinct approach utilizes what it terms "hyperbolic inhibition," a mechanism that modulates NAMPT activity without completely shutting it off. This technique is designed to selectively kill malignant cells while preserving the metabolic function of healthy cells, thereby avoiding the toxicity issues that plagued earlier NAMPT inhibitors.

Remedy Plan's lead asset, RPT1G, is a first-in-class hyperbolic NAMPT inhibitor. Preclinical studies demonstrated that RPT1G is effective in acute leukemia, lymphoma, and solid tumor models and is significantly better tolerated than previous inhibitors. In December 2024, the company initiated a Phase 1 clinical trial in healthy adult volunteers in Australia to evaluate the drug's safety and pharmacokinetic properties. Following the conclusion of this study in May 2025, the company plans to advance RPT1G into a Phase 1/2 trial in the second half of 2025 for patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). Research has also shown that RPT1G may synergize with existing standard-of-care drugs like venetoclax, potentially overcoming treatment resistance. To accelerate these clinical programs and further develop its pipeline for other diseases, Remedy Plan raised over $18 million in May 2025, bringing its total funding to $55 million with backing from investors like Schooner Capital and Alexandria Venture Investments.

Source: Dealroom company data

At a glance

Status
Operational
Employees
20
Open positions
None listed
Dealroom signal
53.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Oncology, Hard Tech, DT and LS, science-based
Technology
Deep Tech
Business model
Manufacturing
Client focus
B2B

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VC✓Equity / VC May 2025 $18M $72M Schooner Capital · Alexandria Venture Investments ↗
LATE VC✓Equity / VC Aug 2023 $19M $76M Undisclosed ↗
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Remedy Plan website traffic

Latest recorded traffic for Remedy Plan is 1K monthly website visits, down 66.7% over the last three months. Remedy Plan's team grew 42.9% over the past year.

Latest monthly visits1K 3-month web change-66.7% 1-year team growth+42.9%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Remedy Plan in the Gaithersburg ecosystem

Live from Dealroom

The Remedy Plan office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Schooner Capital

Series B and later1 investor entered at this stage

  • Alexandria Venture Investments
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States89.5%
🇬🇧 United Kingdom5.3%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Remedy Plan on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Remedy Plan’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.